Podcast appearances and mentions of anthony demaria

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of myocardial infarction in women, in particular. There has been an explosion of interest and research in this entity in the past 5 years, but much remains to be studied. In this interview, Anthony DeMaria moderates a discussion between Esther Kim and Malissa Wood about what we know and what we don’t know about SCAD.

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

Can we discover new therapies for the heart with stem cells? From finding safer medication to preventing cardiac arrest, experts share the latest in the field of cardiac stem cell research. Moderated by Anthony DeMaria, MD, UC San Diego Pat Farrant: Patient Perspective Deepak Srivastava, MD, Gladstone Institutes: Cellular Reprogramming Approaches for Heart Disease Mark Mercola, PhD, Stanford University: Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity Deborah K. Lieu, PhD, UC Davis: The quest for pacemaking cardiomyocytes to engineer biopacemakers Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 36336]

In this interview, Anthony DeMaria and Finn Gustafsson discuss improving quality of life for patients with advanced heart failure and a left ventricular assist device. What does the evidence tell us?

In this special episode of the View, Dr. Peter Block and Dr. Anthony DeMaria discuss highlights from Day 4 of TCT.19, including the cost-effectiveness analysis from MitraClip in heart failure and severe secondary mitral regurgitation (COAPT Cost-Effectiveness Analysis) and health status outcomes from transcatheter aortic valve replacement vs. surgical aortic valve replacement in severe aortic stenosis patients at low-surgical risk (PARTNER 3).

In this special episode of the View, Dr. Peter Block and Dr. Anthony DeMaria discuss highlights from Day 3 of TCT.19, including MitraClip in heart failure and severe secondary mitral regurgitation (COAPT Three-Year Outcomes), transcatheter aortic valve replacement vs. surgical aortic valve replacement in intermediate-risk severe aortic stenosis (PARTNER 2A), percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting left main coronary artery disease (EXCEL), and complete staged revascularization vs. infarct artery PCI in acute myocardial infarction and multivessel disease (COMPLETE Timing Substudy).

In this special episode of the View, Dr. Peter Block and Dr. Anthony DeMaria discuss highlights from Day 2 of TCT.19, including Portico vs. commercially available transcatheter aortic valves in severe aortic stenosis (AS) (PORTICO IDE), ACURATE Neo vs. SAPIEN 3 bioprosthesis in severe AS (SCOPE I), subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves (PARTNER 3 Low-Risk Computed Tomography Substudy), and 1-year outcomes of transcatheter mitral valve repair for degenerated mitral bioprotheses (Mitral Valve-in-Valve).

Dr. Anthony DeMaria and Dr. C. Michael Gibson Discuss

In this interview, Anthony DeMaria and Brian Olshansky discuss the new 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope.

Follow:  @1liquid.artisan4 @campariamerica @campariusa

#13. Underground Bar Brawl Club (UBBC) Last Matador Standing: Shauna VS. Ramon... a birthday rematch. Recorded live at Casa Del Matador in Downtown Summerlin w/ cohost: Anthony Demaria. A good time was had by all.